Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Voretigene neparvovec-rzyl (Luxturna) for inherited retinal dystrophy.

The Medical letter on drugs and therapeutics - 26 Mar 2018

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to cis-trans-Isomerases
Share to Dependovirus
Share to Genetic Predisposition to Disease
Share to Genetic Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Vectors

Share to Heredity

Share to Retinal Dystrophies

Share to Treatment Outcome

Source

Identifiers

PMID: 29635265

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Voretigene neparvovec-rzyl (Luxturna) for inherited retinal dystrophy.PMID 29635265Read ↗

Retinal Dystrophies and the Road to Treatment: Clinical Requirements and Considerations.Semantic proximity Read ↗

Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutationSemantic proximity Read ↗

12-month outcomes after voretigene neparvovec gene therapy in paediatric patients with RPE65 -mediated inherited retinal dystrophySemantic proximity Read ↗

Surgical Aspects in Gene Therapy for Inherited Retinal Diseases.Semantic proximity Read ↗

Voretigene neparvovec-rzyl for treatment of RPE65-mediated inherited retinal diseases: a model for ocular gene therapy developmentSemantic proximity Read ↗

Single Center Experience with Voretigene Neparvovec Gene Augmentation Therapy in RPE65 Mutation-Associated Inherited Retinal Degeneration in a Clinical Setting.Semantic proximity Read ↗

How long does gene therapy last? 4-year follow-up of phase 3 voretigene neparvovec trial in RPE65-associated LCA/inherited retinal diseaseSemantic proximity Read ↗

Voretigene Neparvovec: A Review in RPE65 Mutation-Associated Inherited Retinal Dystrophy.Semantic proximity Read ↗

Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Appraisal.Semantic proximity Read ↗

Real-world outcomes of Voretigene Neparvovec: a single-centre consecutive case series.Semantic proximity Read ↗

Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years.Semantic proximity Read ↗

Visual function and retinal changes after voretigene neparvovec treatment in children with biallelic RPE65-related inherited retinal dystrophySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.